News

News 23.07.2025 Schlieren / Zurich, Switzerland, 22 July, 2025 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, has published preclinical data in PLOS Pathogens demonstrating the discovery and characterization of its lead clinical asset, potravitug, a highly potent human monoclonal antibody, neutralizing...

News 18.07.2025 vVARDIS, a Swiss high growth dental company, and OrbiMed have closed a $50 million funding round, building on OrbiMed's initial $35 million investment, which closed in February. The total capital will be used to refinance existing facilities and support the company's growth initiatives and continued global commercial expansion of their...

News 18.07.2025 Rapidly identifying certain bacteria allows antibiotic treatments to be optimised. A team from the University of Zurich, supported by the SNSF, has developed molecules to detect and capture certain species. The discovery of antibiotics revolutionised medicine in the 20th century, saving countless lives. However, the emergence of resistant bacteria has quickly...

News 23.06.2025 June 19, 2025  - Zurich, Switzerland | Lisbon, Portugal Brenus Pharma, a French biotech developing next-generation first-in-class immunotherapies, and InSphero, a Swiss leader in 3D cell-based assay technologies, presented promising data at the European Association for Cancer Research 2025 annual congress. These data confirm the use of 3D tumor spheroids for potency testing of...

News 23.06.2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, June 22, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”) and...